Intratumoral accumulation of gut microbiota facilitates CD47-based immunotherapy via STING signaling
Open Access
- 30 April 2020
- journal article
- research article
- Published by Rockefeller University Press in The Journal of Experimental Medicine
- Vol. 217 (5)
- https://doi.org/10.1084/jem.20192282
Abstract
Most studies focus on how intestinal microbiota influence cancer immunotherapy through activating gut immunity. However, immunotherapies related to innate responses such as CD47 blockade rely on the rapid immune responses within the tumor microenvironment. Using one defined anaerobic gut microbiota to track whether microbiota interact with host immunity, we observed that Bifidobacterium facilitates local anti-CD47 immunotherapy on tumor tissues through the capacity to accumulate within the tumor microenvironment. Systemic administration of Bifidobacterium leads to its accumulation within the tumor and converts the nonresponder mice into responders to anti-CD47 immunotherapy in a stimulator of interferon genes (STING)-and interferon-dependent fashion. Local delivery of Bifidobacterium potently stimulates STING signaling and increases cross-priming of dendritic cells after anti-CD47 treatment. Our study identifies the mechanism by which gut microbiota preferentially colonize in tumor sites and facilitate immunotherapy via STING signaling.Funding Information
- Ludwig Foundation
- Foglia Foundation
- National Institutes of Health
- National Cancer Institute (R21 CA231273-01, CA141975)
- Cancer Prevention and Research Institute of Texas (RR150072, RP 180725)
This publication has 37 references indexed in Scilit:
- Commensal Bifidobacterium promotes antitumor immunity and facilitates anti–PD-L1 efficacyScience, 2015
- CD47 blockade triggers T cell–mediated destruction of immunogenic tumorsNature Medicine, 2015
- The Intestinal Microbiota Modulates the Anticancer Immune Effects of CyclophosphamideScience, 2013
- Commensal Bacteria Control Cancer Response to Therapy by Modulating the Tumor MicroenvironmentScience, 2013
- The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumorsProceedings of the National Academy of Sciences of the United States of America, 2012
- Therapeutic Antibody Targeting of CD47 Eliminates Human Acute Lymphoblastic LeukemiaCancer Research, 2011
- Anti-CD47 Antibody Synergizes with Rituximab to Promote Phagocytosis and Eradicate Non-Hodgkin LymphomaCell, 2010
- Induction of Intestinal Th17 Cells by Segmented Filamentous BacteriaCell, 2009
- Synbiotic therapy (Bifidobacterium longum/Synergy 1) initiates resolution of inflammation in patients with active ulcerative colitis: a randomised controlled pilot trialGut, 2005
- Cross-priming of CD8+ T cells stimulated by virus-induced type I interferonNature Immunology, 2003